Synchronous gastric cancer complicated with chronic myeloid leukemia (multiple primary cancers): A case report

Yong-Xun Zhao, Ze Yang, Li-Bin Ma, Jia-Yao Dang, Hui-Ying Wang

Abstract

BACKGROUND

With the advancement of medical technology and improvement in living standards, the incidence of multiple primary cancers has gradually increased. In particular, tumors of the digestive system account for a large proportion of multiple primary cancers. The diagnosis and treatment of chronic myeloid leukemia, particularly with synchronous gastric cancer, at the first consultation is relatively rare.

CASE SUMMARY

Herein, we present the case of a middle-aged man who was referred to the Department of Hematology owing to an elevated white blood cell count. After the examination, he was diagnosed with chronic myeloid leukemia and was administered imatinib. Three months after the initial diagnosis, he visited our hospital again for abdominal pain, and further examination revealed gastric malignancy. After discussion with a multidisciplinary team, S-1 (Tegafur, Gimeracil, and Oteracil Potassium Capsules) combined with oxaliplatin—SOX regimen—was initiated. Later, the patient’s condition rapidly progressed. He developed colonic obstruction and underwent an ostomy; however, he died less than 6 months after the initial diagnosis.

CONCLUSION

Multiple primary cancers are influenced by environmental and genetic factors; a standardized multidisciplinary discussion plays a key role in treatment.

Key Words: Multiple primary cancers; Gastric cancer; Leukemia; Leukemia inhibitory factor; Case report
Core Tip: Digestive system tumors consist of a large proportion of multiple primary cancers. In this study, we present the case of a patient with gastric cancer and concomitant chronic myeloid leukemia. To better diagnose and treat such patients, we reviewed the literature available on leukemia complicated by gastric cancer-related multiple primary cancers and analyzed its disease mechanisms, clinical symptoms, and treatment alternatives. This study will be a useful reference for the diagnosis and treatment of patients with such conditions.

Citation: Zhao YX, Yang Z, Ma LB, Dang JY, Wang HY. Synchronous gastric cancer complicated with chronic myeloid leukemia (multiple primary cancers): A case report. World J Clin Cases 2022; 10(30): 11146-11154
URL: https://www.wjgnet.com/2307-8960/full/v10/i30/11146.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i30.11146

INTRODUCTION
Among malignant tumors, gastric cancer has the highest morbidity and mortality. Patients with early gastric cancer often exhibit no overt symptoms, whereas those with advanced gastric cancer may present with abdominal distention, discomfort, nausea, vomiting, hematemesis, and melena. In contrast, leukemia is a malignant clonal disease of hematopoietic stem cells. The primary clinical manifestations of leukemia include anemia, abnormal coagulation, fever, susceptibility to infection, hepatosplenomegaly, lymphadenopathy, and ostealgia[1]. The administration of chemotherapy drugs, such as imatinib, has resulted in a better prognosis and improved quality of life in patients with leukemia and gastric cancer[2].

Cases of patients with multiple primary cancers involving gastric cancer combined with leukemia are extremely rare, and diagnosis and treatment of this condition is difficult. Wang reported the case of an older patient with acute leukemia complicated by gastric cancer who presented with abdominal pain and discomfort but eventually died of multiple organ failure 1 mo after consultation[3]. This patient was initially diagnosed with chronic myeloid leukemia and then with gastric cancer 1 mo later.

Diagnosis of such patients is extremely difficult, and we reviewed the literature that could be relevant in the diagnosis and treatment of such patients.

CASE PRESENTATION

Chief complaints
The patient was a 43-year-old male farmer who was admitted to the hospital owing to the diagnosis of chronic myeloid leukemia for 3 mo and a 1-mo history of intermittent vomiting.

History of present illness
The patient showed an elevated white blood cell count during the national grassroots public welfare physical examination at a local hospital 3 mo before admission. He did not report fever, chills, low-grade fever, night sweats, dizziness, headache, or rash. Next, he was referred to a higher-level hospital for a more thorough blood examination, which revealed the following results: red blood cell count, 3.57 $\times$ 10$^{12}$/L; white blood cell count, 150.27 $\times$ 10$^9$/L; promyelocyte percentage, 15%; mature lymphocyte percentage, 60%; and mature monocyte percentage, 15%. Later, inpatient examination revealed the following results: white blood cell count, 136.59 $\times$ 10$^9$/L, red blood cell count, 3.82 $\times$ 10$^{12}$/L; neutrophil percentage, 90.7%; and neutrophil count, 123.98 $\times$ 10$^9$/L. T and B lymphocyte immune function test revealed the following findings: cluster of differentiation (CD)3+, 31.2%; CD3+ and CD4+, 15.7%; CD3+ and CD8+, 12.0%; CD4+/CD8+, 1.31%; and CD3− and CD19+, 4.5%. The bone marrow cytology test revealed the following findings: (1) Myeloid hyperplasia was observed to a significant extent with 93.5% myeloid cells and 6.5% erythroid cells; (2) The granule:red ratio was 14.38:1; (3) The myeloid system was abnormally hyperplastic, particularly with middle and late myelocytes; eosinophils, basophils, and mitotic cells were also observed; (4) The extent of erythroid hyperplasia was relatively low; (5) A decreased proportion of lymphocytes was observed; and (6) Seven megakaryocytes, which were granular giant cells, were observed within 1 wk.

Identifying middle and late myelocytes on blood films was easy. The size of the red blood cells did not change, the bone marrow smear filling was acceptable, and platelets were scattered and clustered. At this stage, chronic myeloid leukemia was considered. The leukemia immunophenotyping test
revealed the following results: A blast cell area accounting for approximately 0.6% of nuclear cells was observed; increased proportion of granulocytes by approximately 90.7% was noted; fully expressed cMPO, CD13, CD33, and CD64 along with partially expressed CD16, CD15, CD11b, CD10, and CD4 were observed, and the remaining were negative. An early myeloid development pattern was observed, with most development observed in the middle stage; therefore, mature granulocyte proliferative disease (chronic phase chronic myeloid leukemia) was considered. The level of P170 (CD243) was 0.2%. The digital quantitative analysis test detected the BCR-ABL-p210 fusion gene. Chest computed tomography (CT) scan revealed the following results: (1) Micronodules were observed in the posterior segment of the left upper lobe apex, which could be old lesions; and (2) The local bone of the left fifth anterior rib was rough and dense, which could be an old fracture. Color Doppler showed slight tricuspid valve and aortic regurgitation but normal left ventricular systolic and diastolic function.

At this point, the diagnosis of chronic myeloid leukemia was clear (Figure 1), and symptomatic treatment (alkalization, hydration, and plasma cells) was provided. After the white blood cell count reduced to a safe level, he was treated with imatinib mesylate and discharged. One month after discharge, the patient developed pain in the left lower extremity, which was not reported in the consultation. Later, he developed nausea, which was relieved after vomiting a small amount of gastric content. This was accompanied by a productive cough with white sticky sputum, but he did not show fever, chills, abdominal pain, or diarrhea. His body weight decreased by 7.5 kg over 3 mo.

History of past illness
The patient was a healthy individual without diabetes, hypertension, or other underlying diseases.

Personal and family history
The patient had no contributory family history.

Physical examination
Physical examination showed slight abdominal tenderness, with no rebound tenderness and tension.

Laboratory examinations
For further diagnosis and treatment, we performed a series of laboratory and imaging examinations. The results of the blood routine and biochemical tests were normal. The four tests for hematopoiesis showed a slight decrease in vitamin B12 and ferritin levels.

Imaging examinations
CT examination of the chest and abdomen showed an increase in the thickness of the wall of the gastric antrum and pylorus. It revealed a blurred surrounding fat space and the presence of multiple enlarged lymph nodes in the cardia, hepatic hilum, greater omentum, and retroperitoneum (Figure 2). A whole body bone scan revealed abnormal bone metabolism in the bilateral scapula, rib, and iliac bone; thus, multiple bone metastases were considered (Figure 3). Meanwhile, gastroscopy showed the presence of a large amount of retained material in the gastric cavity; yellowish mucus; and huge ulcers in the lower part of the gastric body, gastric angle, and gastric antrum. Although the pylorus was deformed, the lens body could pass through it. These findings were suggestive of gastric cancer (Borrmann type IV) with bile reflux 2 and reflux esophagitis grade C (Figure 4).

Pathology
Pathological analysis revealed a small number of atypical cells in the gastric antrum. Immunohistochemical results were as follows: CKL(2+), CD56(−), ki67 (40%), CD68 (focal 1+), her-2(1+), MPO(−), CD117(−), CD15 (focal 1+), and CD34 (vascular+). Considering the results of morphological and immunohistochemical analyses (Figure 5), poorly differentiated adenocarcinoma was diagnosed.

FINAL DIAGNOSIS
Based on the patient’s medical history, clinical characteristics, and diagnostic results, the final diagnosis was advanced gastric cancer, abdominal lymph node metastasis, bone metastasis, and chronic myeloid leukemia.

TREATMENT
Owing to the distinct condition of the patient, we opted to conduct a multidisciplinary discussion on this case. It was decided that imatinib (400 mg, once daily) administration was to be continued for chronic myeloid leukemia and SOX regimen to be started for gastric cancer with bone metastasis. Antiemetics and acid-suppressing drugs were used as adjuvant therapy.
Figure 1 The patient’s karyotype is 46, XY, t (9;22) (q34;q11). A: The typical translocation between the chromosomes 9 and 22 was found in all 20 metaphase cells analyzed; B-D: Bone marrow smear shows an extremely active cellular proliferation, myeloid cells that are dominated by myelocytes and metamyelocytes, and easily observable/high rate of eosinophils and basophils.

Figure 2 Computed tomography images show gastric cancer. A: Computed tomography (CT) in venous phase show edematous and thickened gastric wall; B: CT in the arterial phase, the gastric wall was thickened and significantly enhanced.

OUTCOME AND FOLLOW-UP

The patient had severe nausea and vomiting during the second cycle of chemotherapy, which was attributed to incomplete intestinal obstruction (Figure 6). However, the obstruction was not relieved after conservative treatment, and exploratory laparotomy and ileostomy were performed.

Following laparotomy, we found severe adhesion of the gastric antrum and colonic hepatic flexure. Portions of the small intestine, ascending colon, and transverse colon showed considerable dilatation. Multiple white, hard nodules were observed in the small mesentery. Considering the preoperative examination results, we decided to perform terminal ileal double-lumen fistula. An area of 1 cm around the right McBurney’s point was considered the stoma. The skin and subcutaneous tissue were incised layer-by-layer, and the terminal double ileum was led out through the ileocecal region, 15 cm away from the ileocecal opening. A double-lumen stoma was performed, and the stoma was sutured layer-by-layer for reinforcement.
Figure 3  Emission computed tomography images show abnormal bone metabolism in the bilateral scapulae, ribs, and ilium; multiple bone metastases were considered.

Figure 4 Gastroscopic images show gastric cancer (Bowman type IV). A: A large amount of retained material in the gastric cavity and huge ulcers in the lower part of the gastric body, angle, and antrum; B: The ulcers base is uneven, brittle, and easy to bleed. Local peristalsis has disappeared.

During the operation, several hard nodules were harvested for subsequent biopsy, which revealed metastatic adenocarcinoma (Figure 7). After discharge, the patient unfortunately passed away in December 2021 (less than 6 mo since the first consultation).

**DISCUSSION**

The continuous progress in medicine and improvement in living standards have extended the lifespan of humans. In addition, the detection rate of multiple primary cancers has gradually increased[4].

Duplicate carcinoma was first reported by Billroth in 1879. Also referred to as multiple primary malignant tumors, duplicate carcinoma involves the simultaneous or successive occurrence of two or more different pathological tissue types in the same organ or tissue in different parts of the same individual. Briefly, it is the presence of two or more primary malignancies. According to the time of appearance of the second malignant tumor, multiple primary cancers can be categorized into synchronous multiple primary cancers (interval of < 6 mo) and metachronous multiple primary cancers (interval ≥ 6 mo). The diagnostic criteria for multiple primary cancers are as follows: (1) Each tumor is malignant; (2) Each tumor occurs in different parts and exists independent of each other; (3) Each tumor has unique morphological characteristics and its own metastatic pathway; and (4) Tumors showing recurrence and metastasis are excluded[5].

There are several pathogenic mechanisms underlying multiple primary cancers, and the most studied mechanisms are those underlying the carcinogenic effects of radiotherapy and chemotherapy, environmental factors, genetic factors, and gene interactions. A previous study reported the case of a woman who underwent total gastrectomy for advanced gastric cancer and received regular postoperative TS-1...
Chemotherapy; she was eventually diagnosed with secondary chronic myeloid leukemia after 3 years [6]. Another older male patient underwent gastric cancer surgery and was diagnosed with chronic myeloid leukemia 2 years after TS-1 chemotherapy [7]. Furthermore, chronic myeloid leukemia has been reported after chemotherapy using drugs other than TS-1 [8]. Moreover, postoperative follow-up studies have shown that patients with breast cancer who received radiotherapy and chemotherapy after surgery have a substantially higher chance of developing multiple primary cancers [9]. Furthermore, environmental factors, such as long-term exposure to chemical and radioactive substances, may be associated with the occurrence of multiple primary cancers [10]. The incidence and prognosis of multiple primary cancers vary among different ethnic groups, which might be because of the effects of genetic factors [11].

A retrospective analysis of cervical cancer and endometrial cancer showed that radiation therapy, smoking, and human papillomavirus infection were significantly associated with the risk of multiple primary cancers [12]. Moreover, frequent exposure to radioactive substances, especially I\textsubscript{131} therapy, increased the risk of second primary cancer after thyroid cancer surgery. Because of the limited number of cases of multiple primary cancers and the lack of research at present, the mechanism underlying gene interaction in the occurrence of multiple primary cancers remains unelucidated.

The patient in this case was a middle-aged man from a rural area who had no bad living habits. He had an acute onset and rapid disease progression, which may be attributed to multiple factors. First, his nutritional status was poor, with reduced immune surveillance capacity. Second, there may be a genetic interaction between the first primary cancer leukemia and gastric cancer. In particular, leukemia inhibitory factor and myeloid leukemia-1 are differentially expressed in the tissues of patients with...
leukemia and gastric cancer, and both play key roles in disease development. However, further studies on the interaction mechanism are warranted [13-16]. Third, during the treatment for leukemia with imatinib, the patient showed severe adverse gastrointestinal reactions, which necessitated short-term drug suspension (4 d) treatment, thereby resulting in the rapid progress of gastric cancer.

In patients with leukemia and gastric cancer, the clinical symptoms associated with leukemia and gastric cancer can either appear simultaneously or successively. The diagnosis is primarily based on blood routine, bone marrow biopsy, imaging, gastroscopy, and pathological analyses. In terms of treatment, acute leukemia is preferentially treated when it is associated with gastric cancer. When gastric cancer is complicated by bleeding, obstruction, and other emergencies, prioritizing the treatment of gastric cancer is essential. However, the effect of imatinib in the development of chronic myeloid leukemia secondary to gastric cancer chemotherapy should be noted. In cases of gastric cancer complicated by leukemia, a multidisciplinary discussion on several fields, including radiology, pathology, gastroenterology, hematology, radiotherapy, and general surgery, is ideal for formulating the best treatment plan for the patient [17,18].

Metachronous duplication carcinoma has a significantly better survival time and prognosis compared with synchronous duplication carcinoma owing to early detection of the second primary cancer of metachronous duplication carcinoma [19]. Existing studies have reported that early diagnosis and treatment can substantially improve the survival and prognosis of patients with multiple primary cancers.

This patient had abdominal discomfort at the initial diagnosis and underwent abdominal B-ultrasound examination; however, gastric cancer was not detected. Advanced gastric cancer was detected on CT conducted after 1 mo of abdominal pain and discomfort. In such patients, routine chest and abdominal plain CT examinations at the initial diagnosis can be useful in the timely detection of multiple primary cancers. In addition, for further diagnosis and treatment of such patients, particular gastric cancer types—such as hepatoid adenocarcinoma of the stomach, lymphoepithelioma-like gastric carcinoma, and hereditary diffuse gastric cancer (HDGC)—cannot be ignored. Tumor markers, gastrin, C14 urea breath testing, CHD1 detection, and colonoscopy are useful in the diagnosis and treatment of
these patients\cite{20-22}.

**CONCLUSION**

Despite the rapid progress in medical technology, more studies should be conducted for the timely diagnosis and treatment of patients with gastric cancer complicated by chronic myeloid leukemia. There is an urgent need to strengthen the understanding of recurrent cancer. For patients with high-risk factors for multiple primary cancers, conducting more comprehensive examinations, formulating an appropriate diagnosis, and ensuring adequate treatment and follow-up are critical. Appropriate guidelines regarding the diagnosis and treatment of recurrent cancer are required in addition to multidisciplinary discussions to formulate optimal treatment plans for patients with multiple primary cancers. Simultaneous gastric cancer with chronic myeloid leukemia has a worse prognosis and shorter survival time than its metachronous counterpart. The pathogenesis of gastric cancer complicated by chronic myeloid leukemia should be further studied because of the current challenges in the diagnosis and treatment of patients with malignant tumors.

**ACKNOWLEDGEMENTS**

We wish to thank all the medical workers involved in the diagnosis and treatment of this patient, especially the multidisciplinary team of the First Hospital of Lanzhou University for their guidance in the diagnosis and treatment.

**FOOTNOTES**

**Author contributions:** Zhao YX, Yang Z, and Dang JY performed the experiments and image acquisition; Zhao YX, Yang Z, Ma LB, and Wang HY designed the study and wrote the manuscript; Zhao YX, Yang Z, and Ma LB edited the manuscript.

**Supported by** Natural Science Foundation of Gansu Province, China, No. 17JR5RA272; Research Fund project of The First Hospital of Lanzhou University, No. Idyyyn2021-120, No. Idyyyn2020-98, and No. Idyyyn2021-30.

**Informed consent statement:** This study was approved by the Ethics Committee of the First Hospital of Lanzhou University. The patient was not required to provide informed consent, as the analysis used anonymized clinical data, obtained after obtaining written consent to treatment.

**Conflict-of-interest statement:** All authors have no conflicts of interest to declare.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016) and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Ze Yang 0000-0003-4546-9753.

**S-Editor:** Wu YXJ

**L-Editor:** A

**P-Editor:** Wu YXJ

**REFERENCES**

1. Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. *Nat Rev Clin Oncol* 2019; 16: 684-701 [PMID: 31278397 DOI: 10.1038/s41571-019-0239-8]

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin* 2021; 71: 7-33 [PMID: 33433946 DOI: 10.3322/caac.21654]
Zhao et al. Multiple primary cancers: A case report

3 Dongchu W, Rong Z. A case of gastric cancer with acute leukemia synchronous duplication carcinoma. *Hainan Medical Journal* 2018; 29: 1615-1616 [DOI: 10.4103/jmjp.jmjp_15_17]

4 Zheng X, Li X, Wang M, Shen J, Sisti G, He Z, Huang J, Li YM, Wu A; Multidisciplinary Oncology Research Collaborative Group (MORCG). Second primary malignancies among cancer patients. *Ann Transl Med* 2020; 8: 638 [PMID: 32566575 DOI: 10.21037/atm-20-2059]

5 Copur MS, Manaparum S. Multiple Primary Tumors Over a Lifetime. *Oncology* 2019; 33 [DOI: 10.1093/annonc/mdf088]

6 Hiiguchi M, Nishinak H, Yamano Y. Differences in Acetic Acid Ototoxicity in Guinea Pigs are Dependent on Maturity. *Otolaryngol (Sunnyvale)* 2015; 5: 208 [DOI: 10.4172/2161-119X.1000208]

7 Miyati T, Inai H, Ogura A, Doi T, Tsuchihashi T, Machida Y. Novel SNP determination method in parallel MRI. *SPIE 6142, Medical Imaging 2006: Physics of Medical Imaging, 61423O* [cited 2 March 2006] [DOI: 10.1117/12.634842]

8 Tsuzaki K, Handa K, Yamamoto K, Hasegawa A, Yamamoto Y, Watanabe M, Mizuta S, Maruyama F, Okamoto M, Emi N, Ezaki K. Chronic myeloid leukemia following chemotherapy with 5'-deoxy-5-fluorouridine for gastric cancer. *Intern Med* 2008; 47: 1739-1741 [PMID: 18827747 DOI: 10.2169/internalmedicine.47.1072]

9 Jabagl MJ, Goncalves A, Vey N, Le Tri T, Zureik M, Dray-Spira R. Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer. *Cancers (Basel)* 2019; 11 [PMID: 35169513 DOI: 10.3390/cancers11101463]

10 Nosrati A, Yu WY, McGuire J, Griffin A, de Souza JR, Singh R, Linos E, Chren MM, Grimes B, Jewell NP, Wei ML. Outcomes and Risk Factors in Patients with Multiple Primary Melanomas. *J Invest Dermatol* 2019; 139: 195-201 [PMID: 30031745 DOI: 10.1016/j.jid.2018.07.009]

11 Sidhom F, Jackson D, Ali A, Shokrani B, Taddesse-Heath L. Multiple Primary Malignant Neoplasms in African Americans: A Case Series and Literature Review. *Cureus* 2022; 14: e21585 [PMID: 35228943 DOI: 10.7759/cureus.21585]

12 Huang K, Xu L, Jia M, Liu W, Wang S, Han J, Li Y, Song Q, Fu Z. Second primary malignancies in cervical cancer and endometrial cancer survivors: a population-based analysis. *Aging (Albany NY)* 2012; 14: 3836-3855 [PMID: 35507749 DOI: 10.18632/aging.204047]

13 Xu Z, Chen J, Shao L, Ma W, Xu D. Promyelocytic leukemia protein enhances apoptosis of gastric cancer cells through Yes-associated protein. *Tumour Biol* 2015; 36: 8047-8054 [PMID: 25971581 DOI: 10.1007/s13277-015-3539-3]

14 Xu G, Wang H, Li W, Xue Z, Luo Q. Leukemia inhibitory factor inhibits the proliferation of gastric cancer cells by inducing G1-phase arrest. *J Cell Physiol* 2019; 234: 3613-3620 [PMID: 30565675 DOI: 10.1002/jcp.27083]

15 Likui W, Qun L, Wanqing Z, Haifeng S, Fangqiu L, Xiaojun L. Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. *Gastric Cancer* 2019; 22: 396-400 [PMID: 19582795 DOI: 10.1002/sgc.21345]

16 Seencavassan L, Martin OCB, Lehours P, Dubus P, Varon C. Leukaemia inhibitory factor in gastric cancer: friend or foe? *Gastric Cancer* 2022; 25: 299-305 [PMID: 35106710 DOI: 10.1007/s13277-022-02178-w]

17 Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. *J Natl Compr Canc Netw* 2009; 7: 246-312 [PMID: 17439758 DOI: 10.6004/jnccn.2007.0025]

18 Sharma A, Sethi N, Saini S, Pandia K, Jangir R. Primary Ewings sarcoma in liver - A rare case report with review of literature. *Indian J Pathol Microbiol* 2021; 64: S136-S139 [PMID: 34135155 DOI: 10.4103/ijpmp.IJPMP_288_19]

19 Ochiai K, Kawai K, Nozawa H, Sasaki K, Kaneko M, Murono K, Emoto S, Ishii H, Sonoda H, Yamauchi S, Sugihara K, Ishihara S. Prognostic Impact and Clinicopathological Features of Multiple Colorectal Cancers and Extracolorectal Malignancies: A Nationwide Retrospective Study. *Digestion* 2021; 102: 911-920 [PMID: 34261059 DOI: 10.1159/000517271]

20 Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. *Gastric Cancer* 2010; 13: 1-10 [PMID: 20373070 DOI: 10.1007/s12029-009-0531-x]

21 Yu C. Comment on: “Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. *Gastric Cancer* 2019; 1-10” by Wang Y, Sun L, Li Z, Gao J, Ge S, Zhang C, Yuan J, Wang X, Li J, Lu Z, Gong J, Lu M, Zhou J, Peng Z, Shen L, Zhang X. *Gastric Cancer* 2019; 22: 1312 [PMID: 31444590 DOI: 10.1007/s12029-019-09996-x]

22 Guimarães N, Bolais Monica I, Oliveira S, Pato Pais D, Andrade S, Bertao Colaco I, Vila Nova C, Vieira V, Azenh A, Fonseca Pinho J, Guedes F, Conecido L, Valente Cecilio J. Lymphoepithelioma-like Gastric Carcinoma and Gastric Involvement of Chronic Lymphoproliferative Lesions: Two Rare Identities Coexisting in One Patient. *J Med Cases* 2022; 13: 36-39 [DOI: 10.7759/cureus.2405]
